



AWTTC

All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

Table 3. Costs per patient, per regimen, per year

Intervention	Regimen	Cost per patient			
		Acquisition	Administration	Resource	Adverse event
Neoadjuvant treatment +/- adjuvant treatment according to response					
Neoadjuvant nivolumab plus ipilimumab	Nivolumab IV 240 mg plus ipilimumab IV 80 mg every three weeks for a total of 2 cycles	¶¶¶	£591	£909	£145
Neoadjuvant nivolumab plus ipilimumab plus adjuvant dabrafenib and trametinib	Neoadjuvant nivolumab IV 240 mg plus ipilimumab IV 80 mg every three weeks for a total of 2 cycles Adjuvant oral dabrafenib 150 mg twice daily plus trametinib 2 mg once daily for a total of 46 weeks	¶¶¶	£859	£3,230	£213
Neoadjuvant nivolumab plus ipilimumab plus adjuvant nivolumab monotherapy	Neoadjuvant nivolumab IV 240 mg plus ipilimumab IV 80 mg every three	¶¶¶	£3,747	£3,230	£191

Intervention	Regimen	Cost per patient			
	weeks for a total of 2 cycles Nivolumab IV 480 mg every 4 weeks for 11 cycles or nivolumab SC 1,200 mg every 4 weeks for 11 cycles				
Comparators – NHS Wales standard of care					
Adjuvant treatment - dabrafenib and trametinib	Oral dabrafenib 150 mg BD plus trametinib 2 mg OD every 4 weeks for 13 cycles	¶¶¶	£268	£2,840	£68
Adjuvant treatment - nivolumab monotherapy	1,200 mg SC every 4 weeks for 13 cycles	¶¶¶	£3,736	£2,840	£45
Adjuvant treatment – pembrolizumab monotherapy	400 mg IV every 6 weeks for 9 cycles	¶¶¶	£2,576	£1,996	£6.02
<p>¶¶¶: commercial in confidence figure removed Sources for costs are outlined below.</p> <p>Acquisition: Patient Access Scheme prices. Excludes VAT. Administration: NHS England National Cost Collection Data Publication 2024/25²⁴. Resource: NHS England National Cost Collection Data Publication 2024/25²⁴. Adverse event: NHS England Cost Collection Index 2024/25 and adverse event rates from the following studies: NADINA, KEYNOTE-054, and COMBI-AD^{2,22,24,25}.</p>					